Department of Health – Abu Dhabi strengthens global healthcare ties with Russia
6 Mar 2025 19:55
ABU DHABI (WAM)The Department of Health – Abu Dhabi (DoH) has successfully concluded a strategic delegation visit to Russia.The visit fostered groundbreaking collaborations in healthcare innovation, precision medicine, genomics, and longevity research.The delegation engaged with senior officials, leading research centres, and industry pioneers, aligning with Abu Dhabi's vision to build one of the world's most intelligent and integrated healthcare systems while positioning the emirate as a global hub for life sciences and medical innovation.Led by Dr. Noura Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi (DoH), the Abu Dhabi delegation, met with Mikhail Murashko, Russian Minister of Health. The meeting focused on exploring avenues for collaboration in vaccine development, medical education, genomics and research.The Abu Dhabi delegation also met with prominent Russian institutions, including Sechenov University, the Moscow Institute of Physics and Technology (MIPT), the Dmitry Rogachev National Research Centre, and the Gamaleya National Research Centre, to explore opportunities for academic exchanges, joint research initiatives, and medical education programmes.The discussions highlighted the potential for conducting clinical trials for the newly developed cancer vaccine and enhancing collaboration in genomics, precision medicine, and oncology, and capacity building in communicable diseases. Additionally, the delegation engaged with several Emirati medical students enrolled at leading Russian universities.The delegation explored strategic partnerships with Russia's leading healthcare facilities, including the Medsi Group, the National Medical Center of Oncology (N.N. Blokhin Cancer Center), and the Marshak Clinic. These discussions focused on advanced treatment protocols, rehabilitation services, addiction treatment, and mental healthcare, and opportunities to enhance patient care and treatment outcomes.Recognising the critical role of innovation in shaping the future of healthcare, the delegation met with the Skolkovo Innovation Centre, Russia's leading technology hub, and Biocad Pharmaceutical Company, a prominent biotech and pharmaceutical organisation. The discussions explored collaboration opportunities with biotech and medtech initiatives in Abu Dhabi, strengthening drug availability, particularly in gene therapy and advanced treatment options, and fostering innovation in digital health and precision medicine.Commenting on the success of the visit, Dr. Noura Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi (DoH), stated, 'This mission marks a significant milestone in Abu Dhabi's commitment to advancing global healthcare collaboration. Through our engagements with Russia's leading institutions, we have identified key areas for joint research and innovation. This initiative paves the way for long-term partnerships that will drive excellence in medical research and healthcare delivery for communities around all the world.'
The delegation also extended an official invitation to Russian healthcare leaders to participate in the upcoming Abu Dhabi Global Health Week 2025, reinforcing global cooperation in life sciences and medical research. This premier event will provide a platform for knowledge exchange, strategic networking, and investment opportunities, allowing Russian experts to showcase their innovations while gaining insights into Abu Dhabi's cutting-edge healthcare advancements and regulatory frameworks.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
7 hours ago
- Khaleej Times
UAE: Disease testing in 10 minutes? Abu Dhabi scientists develop affordable tool
A team of scientists at New York University Abu Dhabi has developed a paper-based diagnostic device that can detect infectious diseases in under 10 minutes. The Radially Compartmentalised Paper Chip (RCP-Chip) offers a fast, affordable, and portable solution for on-site screening of infectious diseases without the need for sophisticated lab equipment or trained personnel. Conceived during the early days of the Covid pandemic, the RCP-Chip was designed to address the urgent global need for efficient testing in low-resource and remote settings. 'Our goal was to create something fast, affordable, and easy to use, especially in areas where lab access is limited,' said Mohammad A. Qasaimeh, Associate Professor of Mechanical Engineering and Bioengineering at NYUAD and the senior author of the study. Beyond Covid-19, the chip is easily reconfigurable to test for other viruses and bacteria which causes diseases like chickenpox, dengue and malaria. 'With minor modifications, it can be adapted to diagnose a wide range of diseases or even test hormones and metabolites,' he explained. 'What makes it truly impactful is its real-world potential,' said Pavithra Sukumar, NYUAD Research Assistant and co-first author. 'This portable test could significantly improve outbreak response by enabling faster isolation, treatment, and control.' How it works According to Qasaimeh, the handheld device can be mass-produced and utilised in places where resources are limited. 'It requires minimal number of reagents and sample to run,' he said. 'It needs a heating stage which is around 60 degrees Celsius. This can be achieved by means of a hot plate or an oven. These are commonly founded devices everywhere.' It uses saliva instead of swabs and can be sent to any area very quickly. 'In a short amount of time, you can deploy it for use,' he said. 'That was our other motivation when we were developing it.' Qasaimeh added that it took the team approximately two years to develop due to pandemic-related lab access restrictions. 'In the initial phase, we focused on designing the chip and brainstorming the approaches,' he said. 'After initial curfews, gradually they allowed us to have access to the labs. That is when we started testing the device and deepened the research.' The team has filed a patent and launched a startup to pursue commercialisation, with interest already shown by biotech firms. 'We aim to find investors so that we can continue with the development stage of the device, but this time with its translational potential,' said Qasaimeh. 'This is so that the device is ready to deploy in the markets for different purposes. This device can be modified to be used for other situations as well.'
Arabian Business
11 hours ago
- Arabian Business
UAE midday work ban to begin June 15, Minister inspects Dubai site
UAE businesses will introduce the summer outdoor work ban from Sunday, June 15. Dr. Abdulrahman Al Awar, UAE Minister of Human Resources and Emiratisation and Acting Minister of Higher Education and Scientific Research, visited a Dubai construction site ahead of the implementation of the annual Midday Break. Now in its 21st consecutive year, the Midday Break prohibits outdoor work under direct sunlight between 12.30pm and 3pm daily until September 15, as part of the UAE's commitment to worker welfare and occupational safety. UAE outdoor work ban During the site inspection, Dr. Al Awar, accompanied by senior officials, reviewed Khansaheb Civil Engineering's initiatives to comply with the summer safety mandate. Chairman Tariq Khansaheb detailed the company's measures, including shaded rest zones, cooling devices, and cold drinking water — all designed to safeguard labourers from the effects of extreme heat. Dr. Al Awar praised the company's commitment to corporate social responsibility (CSR) and highlighted the vital role of the private sector in boosting the UAE's global labour competitiveness. The visit also included representatives from Abu Dhabi Islamic Bank, Aster DM Healthcare, and National Food Product Company (NFPC), who contributed by offering workers medical check-ups, gifts, refreshments, and awareness sessions on heat exhaustion prevention. The Ministry of Human Resources and Emiratisation (MoHRE) reiterated that employers must provide shaded areas, adequate hydration, first-aid kits, and cooling solutions at job sites during the break. The ministry encourages community members to report any violations or non-compliance through the MoHRE call centre on 600590000, the official website, or the smart app.
The National
2 days ago
- The National
Emirati man with rare blood disorder benefits from new $2 million gene therapy in the US
An Emirati man with a rare inherited disorder has become only the second patient in the world to benefit from a pioneering $2 million gene therapy that eliminates the need for regular blood transfusions. Khalifa Dawood, 22, from Abu Dhabi said he has been given a 'new lease on life' as he recovers from the novel gene treatment he received at Cleveland Clinic Children's hospital in Ohio, which recently won medical approval for the therapy. The UAE has some of the regions highest rates of thalassaemia, also known as sickle cell disease, a condition that limits the body's ability to produce healthy red blood cells. While some carriers show very limited symptoms, others experience bone deformities, shortness of breath, dizziness, organ damage and heart palpitations. The condition can require regular blood transfusions, with research suggesting thalassaemia affects as many as 16.5 per cent of the population. A new treatment used for the first time by the Cleveland Clinic Children's hospital has proven to modify a patient's blood forming cells, and can be delivered as a one-time treatment called Casgevy. Mr Dawood said that he hoped the treatment would allow him to lead a normal life, without the need for regular hospital stays. 'I am hoping this gives me a new lease on life where I am energised to enjoy it,' he said. Life-changing treatment Since its approval by the US Food and Drug Administration in January, the therapy has been delivered to an American woman from Ohio and Mr Dawood. I am hoping this gives me a new lease on life where I am energised to enjoy it Khalifa Dawood Although the treatment is expensive, it is life changing for those who receive it, according to Dr Rabi Hanna, chairman of the paediatric haematology-oncology department at Cleveland Clinic Children's hospital. It is not uncommon for adults to receive specialist care at a children's centre, particularly for conditions they have had since birth, as is the case with Mr Dawood. 'Unlike regular medicines that people take for years, Casgevy is meant to be a one-time treatment that could last a lifetime,' he said. 'It uses CRISPR gene editing, which is a very advanced science. Editing cells safely and precisely takes a lot of time, technology, and testing. 'It is also custom-made, as Casgevy is made from a person's own cells, which are collected, sent to a lab, edited and then returned. That process is complex and individualised.' The innovative treatment uses a gene editing technology called CRISPR/Cas9 to modify a patient's stem cells. The edited cells are then transplanted back into the patient, where they produce more haemoglobin in new healthy red blood cells. The FDA's approval was based on results from a single arm which showed 91 per cent of patients with beta thalassaemia did not need a blood transfusion for at least a year after having the treatment. Costly medical care Despite the therapy's success, it is likely to remain out of reach for the majority with costs of about $2.2 million. Gene therapies are typically the most expensive medical treatments. Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of haemophilia B, a potentially life threatening disorder that prevents blood from clotting. Priced at about $3.5 million, it was the world's most expensive drug until the arrival of Lenmeldy in March last year. The gene treatment developed by Orchard Therapeutics costs about $4.2 million and is used to treat life threatening nerve disorders in young children. High costs of certain drugs can be covered by insurers, government health systems or charitable foundations when there are no other treatment options. Drug companies also occasionally offer financial support programmes for families in need. The process of administering Casgevy begins by collecting stem cells from the patient's blood that are then sent to the lab to be edited using tiny, precise scissors. By clipping off the DNA responsible for preventing the body making healthy haemoglobin, the repaired cells can then be returned to the body. A course of chemotherapy is then required to clear out the old, sick marrow cells, allowing new healthy ones to grow in their place. Recovery time in the hospital is about four weeks. As the science behind gene editing improves, it should become faster, easier and cheaper to edit cells with higher accuracy, and fewer side effects. 'It is my hope and prediction that price will come down, but I am not sure how quickly,' said Dr Hanna. 'As the science of gene editing improves, it may become faster, easier, and cheaper to edit cells with higher accuracy and fewer side effects. 'Right now, Casgevy is the first gene editing therapy approved for sickle cell and thalassaemia. 'But more companies are developing similar treatments. When that happens, competition can help drive prices down. 'Also as companies learn how to make these therapies at scale, they may reduce production and delivery costs. 'Think of it like early computers or smartphones – they were expensive at first, but prices dropped as technology improved.' Global health drive Although patients like Mr Dawood must travel overseas for expensive gene therapy, the Gulf is also emerging as a go-to destination for emerging treatments. The King Faisal Specialist Hospital & Research Centre in Saudi Arabia is emerging as a leader of regional clinical trials and delivered a breakthrough in haemophilia care, using one-time gene therapy to restore clotting function in eight patients. In the UAE, at Medcare Royal Speciality Hospital Al Qusais, patients are receiving the latest care for rare genetic disorders like spinal muscular atrophy and Duchenne muscular dystrophy, two life-limiting growth conditions. Doctors there said patients were travelling into Dubai from Turkey and elsewhere in the region. Medcare Women and Children Hospital was one of the first private clinics outside the US to administer gene therapy for spinal muscular atrophy, and has since delivered 100 infusions. American Hospital, Al Jalila Children's Hospital and Fakeeh University Hospital also offer gene therapy Zolgensma, which can cost about $2 million per dose. Dr Vivek Mundada, a consultant paediatric neurologist at Medcare Royal Speciality Hospital, said the drug had delivered remarkable outcomes in managing complex genetic conditions. 'Dubai is becoming a centre of medical innovation, and Medcare is proud to be leading that movement, especially in the field of rare genetic diseases,' he said. 'Through our comprehensive, patient-centred care model, we are transforming outcomes for children who previously had limited treatment options.'
